Arcus Biosciences Inc (RCUS) ニュース

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high, locally...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and...

Form 8-K - Current report

First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Objective response rate of 34% (2 responses pending confirmation) and 25% (confirmed) in the 100mg daily dose expansion cohort (n=32) of ARC-20...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and...

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Data from the 100mg expansion cohort of ARC-20, a Phase 1/1b study of casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented...

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

Arcus and AstraZeneca to evaluate their respective molecules in combination to establish a potential first- and best-in-class treatment for...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and...

Form 4 - Statement of changes in beneficial ownership of securities

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and...

Form 8-K - Current report

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

Facility adds operational flexibility and provides funding for the recently announced Phase 3 PEAK-1 study for casdatifan. $150 million...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and...